British Medical Bulletin

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (10) Request Permissions Disclaimer Google Scholar Articles by Cot, M Articles by Deloron, P Search for Related Content PubMed PubMed Citation Articles by Cot, M Articles by Deloron, P Related Collections Infectious Diseases Obstetrics and Gynaecology Social Bookmarking          What's this?

British Medical Bulletin 67:137-148 (2003)
© 2003 Oxford University Press

Malaria prevention strategies

Pregnancy-Associated Malaria (PAM)

M Cot and P Deloron

Institut de Recherche pour le Développement, UR 010, Paris, France

Correspondence to: Michel Cot, IRD UR 010, Faculté de pharmacie, Laboratoire de parasitologie, 4 Avenue de l’Observatoire, 75270, Paris Cedex 06, France. E-mail: Michel.Cot{at}ird.fr

	Abstract

Top Abstract Introduction Consequences of malaria during... Effect of malaria prevention... Conclusions and future research References

 
Acute and severe consequences of pregnancy-associated malaria (PAM), such as materno-fetal death or cerebral malaria, seem limited to unstable malaria areas. In areas of stable endemicity, the main consequences are maternal anaemia and low birth weight (LBW) babies, particularly in primigravidae. Placental malaria seems more frequent and its consequences more severe in HIV-infected women. Since 1964, several chemoprophylaxis controlled trials have been undertaken, mainly in Tropical Africa where malaria is stable. Most showed an increase in mean birth weight in the prophylaxis group, especially among primigravidae. Similar findings were made with anaemia. Prophylaxis seems less effective in the case of HIV–malaria co-infection, which may require an increase in the number of doses. At present, intermittent treatment with sulfadoxine–pyrimethamine given twice or thrice during pregnancy in antenatal clinics seems the best policy for preventing PAM. Such effective prophylaxis should be integrated with other antenatal clinic services. Recently identified molecular receptors involved in cytoadherence of parasitized erythrocytes to placenta could yield new therapeutic or vaccine approaches, specifically targeted to pregnant women.

	Introduction

Top Abstract Introduction Consequences of malaria during... Effect of malaria prevention... Conclusions and future research References

 
The burden of pregnancy-associated malaria in terms of perinatal death and morbidity is often mentioned but seldom incorporated into global initiatives that aim to improve the quality of health services for children and pregnant women, like Safe Motherhood (a partnership of national and international organizations, including UNICEF, WHO and the World Bank). The topic is generally studied by specialists of tropical disease rather than obstetricians or public health policy makers.

However, the impact of this disease during pregnancy was described nearly a century ago¹. These early observations were undertaken during epidemics in areas of low transmission. They showed the particularly dramatic impact of malaria on the health of pregnant women as well as on the outcome of pregnancy. These first studies highlighted the high frequency of maternal deaths and high rates of abortions and stillbirths. Several investigations were subsequently undertaken in hyperendemic areas, chiefly in the 1940s and the 1950s. These showed a lesser impact of malaria probably due to the acquisition of protective immunity by mothers living in these areas.

By the beginning of the 1980s, a general outline of the situation could be drawn², showing that the higher susceptibility of pregnant women to malaria and the association of low birth weight (LBW) and maternal anaemia to malarial infection of the placenta is a public health priority even in high transmission areas. At present, this problem is particularly important in sub-Saharan Africa, where it is estimated that, whereas 24 million women are exposed every year, fewer than 5% have access to effective interventions.

	Consequences of malaria during pregnancy

Top Abstract Introduction Consequences of malaria during... Effect of malaria prevention... Conclusions and future research References

 
Low endemicity areas

Ever since the first observations of epidemics, several epidemiological investigations have been carried out in different areas of low transmission^3–6. The impact of unstable malaria on pregnant women varies according to the intensity of transmission. This is also true for the level of immunity acquired by mothers. The more severe complications of Plasmodium falciparum infection, such as cerebral malaria or pulmonary oedema (which can lead to maternal deaths), affect women with the lowest levels of immunity. Clinical malaria attacks with high fever and maternal anaemia are also frequent in areas of lower endemicity and affect primigravidae and multigravidae indifferently. Abortion, stillbirth and LBW are frequent consequences for the fetus (see Table 1).

View this table: [in this window] [in a new window]   Table 1 Clinical effects of pregnancy-associated malaria

 

High endemicity areas

In settings with stable transmission of P. falciparum malaria, over a hundred studies were published on pregnancy-associated malaria from 1950 to 1990, most involving large samples of women. Comprehensive reviews of these studies have been undertaken^2,7–9. Their conclusions are generally in agreement, and very different from the observations made in areas of unstable malaria (see Table 1).

Maternal morbidity and mortality
Parasitaemia is more frequent and parasite density is higher during the first and, to a lesser extent, the second pregnancy, than in multigravidae or in non-pregnant women. Clinical signs of malaria are not frequent (e.g. fever).

Anaemia is more frequent in pregnant women, and more pronounced in primigravidae than in multigravidae^10–13. The aetiology of anaemia in pregnancy is multifactorial. Causes such as poor nutrition (which induces iron and folate deficiencies), haemoglobinopathies and infection with other parasites (mainly hookworm) add to this syndrome. Most studies show a strong association between malarial infection of the placenta or peripheral blood and haemoglobin levels, confirming that this is a major cause of anaemia, even when other factors are present^12,13.

The effect of maternal anaemia on the course and the outcome of pregnancy is difficult to establish. If WHO standards are considered (haemoglobin <11 g/dl), it appears that a very large proportion of pregnant women living in malaria-endemic areas should be considered anaemic [e.g. 72% in the Democratic Republic of Congo (former Zaire)¹¹ or 94% in Papua-New Guinea¹⁴]. Such mild anaemia does not seem to cause serious problems during pregnancy, as shown by recent studies conducted in developed countries¹⁵ as well as in malaria-endemic countries^5,14. In fact, only severe malaria (defined as haemoglobin <7 g/dl or haemoglobin <8 g/dl, depending on the authors^13,14,16) can be associated with adverse perinatal outcomes, such as maternal mortality (by increasing the severity of postpartum haemorrhage) or LBW of the baby. Prevalence of severe anaemia (<7 g/dl) in highly malaria-endemic zones varies greatly according to the study area (<3% in the Democratic Republic of Congo¹¹, 9–10% in Tanzania and coastal Kenya^12,13). There is a general lack of information on the outcomes for mothers and babies. However, in a comprehensive review of all studies published between 1985 and 2000, Steketee et al⁹ estimated that maternal anaemia contributed to 7–18% of LBW and to 25% of total infant mortality.

Maternal mortality is difficult to estimate in tropical countries where there is a paucity of reliable data. This is particularly true of deaths related to malaria, which have been found to be associated with an increase in pre-eclampsia or postpartum haemorrhage. In addition to the difficulty of assessing a causal relationship between the two factors, the main problem is that diagnosis of malaria is usually based on either clinical examination or verbal autopsy, thus lacking specificity. Parasitological proof is not available in most cases. Based on a review of 23 studies in Africa, Brabin and Verhoeff¹⁷ estimated that 0.5–23% of maternal deaths in hospital settings and 2.9–17.6% in community-based studies are due to malaria. It is interesting to note that one of the most reliable studies, set in Malawi in 1989, reported only 0.9% of deaths directly attributable to malaria. A year-long follow-up of 4053 pregnant women did not show an association between mortality and parasitaemia for mothers¹⁸.

Placental malaria infection
Parasitaemia of the maternal placental blood is more frequent than parasitaemia of the maternal peripheral blood. This affects 10–34% of all pregnant women, depending on the studies^2,7,8, and primigravidae are more heavily and more often infected (up to twice as much) than multigravidae.

Fetal and newborn morbidity
All studies show a constant association between placental infection and LBW, which has a strong impact on neonatal and infant morbidity, particularly for first births. The mean decrease in birth weight associated with placental infection ranges from 55 to 348 g (all parities), equivalent to roughly a two-fold increase in the proportion of LBW, which usually affects 10–15% of births in malaria-endemic areas^2,6,7. Although no complete understanding of the biological mechanism by which placental infection causes LBW has been reached, the combination of intrauterine growth retardation and prematurity is strongly suspected^7,14,19. The overall contribution of maternal malaria to LBW is estimated to be 8–14% of all deliveries in malaria-endemic areas⁹.

It is also difficult to assess the impact of maternal malaria infection on perinatal and infant mortality. Based on the few studies available, Steketee et al.⁹ estimated that pregnancy-associated malaria was responsible for 3–8% of infant deaths (approximately 75,000–200,000 infants every year).

Transplacental infection of the newborn was established as of the 1930s, and its frequency varies highly according to published studies²⁰ (0–29%). No clear explanation has been found to understand such divergence in highly endemic areas. It seems that congenital infection of the baby is well tolerated in such settings, as no adverse effect was reported. Rapid parasite clearance in newborns was observed in the absence of antimalarial treatment in two studies^20,21.

HIV–malaria interaction
Since the onset and the rapid spread of the AIDS epidemic in areas where malaria transmission occurs, questions have arisen concerning a possible interaction between both infections. As HIV infection occurs in 3–27% of pregnant women in areas where malaria is present⁹, this could represent a major public health problem. The first observations in Malawi, where nearly 3000 pregnant women were followed between 1987 and 1989, showed an increase in the parasite prevalence and density in HIV-positive compared with HIV-negative women²². These findings were recently confirmed by two studies in Malawi and Kenya^23,24. Moreover, several studies^22,24 have noted that the usual pattern of increased parasite prevalence and density in primigravidae is altered. HIV-positive primigravidae are at similar risk of malaria as HIV-positive multigravidae.

There are indications that malaria can increase viral loads and mother-to-child HIV transmission^9,25, but this is largely an unresolved question.

Dual infection also influences the outcome of pregnancy. It seems that primigravidae with both infections have a two-fold increase in the risk of delivering a LBW baby compared with women infected with HIV alone²⁶.

	Effect of malaria prevention strategies

Top Abstract Introduction Consequences of malaria during... Effect of malaria prevention... Conclusions and future research References

 
Chemoprophylaxis

The first published randomized trial of chemoprophylaxis by pyrimethamine was carried out in Kenya in 1964²⁷. It was followed by over 30 clinical trials comparing various drugs and regimens, more or less appropriate in terms of randomization and methodology. We refer here to systematic reviews that have been made of these studies^7,28,29.

Table 2 displays a list of the few drugs that are available for prophylaxis in pregnant women, along with their strengths and limitations. Table 3 is a selection of some of the main trials (prophylaxis versus placebo or no intervention) from 1964 to the present, showing a great variety of protocols, interventions, outcomes and results.

View this table: [in this window] [in a new window]   Table 2 Antimalarial drugs currently used for prophylaxis in pregnant women

 

View this table: [in this window] [in a new window]   Table 3 Effect of chemoprophylaxis on maternal and fetal outcomes

 

Regardless of their protocol, all published studies clearly show an important decrease in parasitaemia (of the placental or maternal peripheral blood) in the intervention group. According to the 14 trials included in the 2003 Cochrane database review²⁹, severe antenatal anaemia was less frequent in the group having received prophylaxis (RR = 0.62, 95% CI [0.50; 0.78]). In all studies but one³⁰ (Thailand: unstable malaria), there was an increase in birth weight and a reduction in LBW, particularly in first and second pregnancies (RR = 0.49, 95% CI [0.36; 0.65]), and perinatal mortality seemed to be reduced (see also Table 3).

One of the main problems that appeared during the chemoprophylaxis trials is the growing resistance of the parasites to antimalarial treatments. Very soon after the first trial in Nigeria²⁷, it became obvious that pyrimethamine alone could no longer be used for prophylaxis, as it had lost a great deal of its usefulness. This is why subsequent intervention studies in Africa used dapsone–pyrimethamine or sulfadoxine–pyrimethamine (SP) combinations^31,34. The same problem occurred (albeit to a lesser extent) with chloroquine. It is interesting to note that in our trial (1992) in Cameroon³³, although in vivo resistance attained 10% of the study population, there was still a substantial reduction in LBW in the treated group (Table 3). In areas of multiresistant malaria such as South East Asia, neither chloroquine nor SP combinations could be used, and mefloquine was administered to pregnant women initially³⁰.

Additionally, none of these drugs has been proven to be perfectly safe in pregnancy, except for chloroquine (Table 2). Questions remain about the teratogenic effects of folic acid antagonists (such as in the SP combinations), even if such risk appears to be significant only when treatment is given during the first trimester of pregnancy³⁵ (women usually do not start prophylaxis before the fourth or fifth month). There is also a possible association between the use of mefloquine and an increased risk of stillbirth³⁶. Other drugs, such as tetracycline or halofantrine, are strictly forbidden during pregnancy. Quinine or artemisinin compounds cannot be used as prophylaxis because of their short half-life.

Another concern is the poor compliance generally observed with weekly or bi-monthly chemoprophylaxis, and ineffective blood levels induced from missing out one or several doses of anti-malarial drugs. In contrast, attendance at antenatal clinics (ANC) is generally good, and an important change in prevention strategies has occurred with the introduction of intermittent treatment with SP combinations in Malawi³⁷. With this regimen, a single curative dose of three tablets is given two or three times (depending on the date of the first visit) at ANC visits (see Table 2). Though not evaluated as randomized trials (except one³⁴), this regimen appears to be better accepted by pregnant women as well as being effective on placental infection, severe maternal anaemia and on incidence of LBW^34,37–39. One of these studies³⁸ seems to indicate that placental malaria and LBW for HIV-positive women were improved through SP treatment at over two doses. If confirmed, this may have important consequences on prevention strategies, indicating that HIV-positive women should receive three SP doses at least.

Other protection measures

Vector control measures can act as a complement to prophylaxis to protect pregnant women against malaria. To our knowledge, only the effect of insecticide-treated bed nets (ITBNs) has been evaluated so far. The results are conflicting. Some studies (Thailand, The Gambia) indicate improvement in maternal anaemia, parasitaemia and LBW^40,41. Others (Kenya, Ghana) did not show any noticeable effect of ITBNs on either the mother or the fetus^42,43.

	Conclusions and future research

Top Abstract Introduction Consequences of malaria during... Effect of malaria prevention... Conclusions and future research References

 
The administration of chemoprophylaxis during pregnancy has been proven to prevent placental malaria, maternal anaemia and LBW thanks to the randomized trials carried out in the 1980s and 1990s in highly endemic areas. However, poor compliance with weekly or bi-monthly regimens has led to the promotion of alternative strategies: intermittent treatment with SP combination given at ANC visits. These seem to be effective and more acceptable to pregnant women. This is national policy in several African countries and should be extended to areas where intense transmission of chloroquine-resistant P. falciparum occurs.

Whether to target interventions at high risk groups, such as primigravidae, secundigravidae or HIV-infected women when cost/benefit considerations are taken into account is not an easy question to answer. HIV and malaria co-infection seems to alter the normal pattern of increased susceptibility in primigravidae compared with multigravidae. It may be difficult to differentiate these groups when providing the intervention, as well as to exclude some women from receiving benefit. Therefore, the administration of SP intermittent treatment to all women may be the best strategy, when local resources permit it.

Some problems remain to be resolved. The decreasing efficiency of SP in HIV-positive pregnant women should be confirmed. Alternative drugs to SP should be developed, in case drug resistance intensifies.

These measures should be implemented along with other interventions such as the use of ITBNs, the systematic treatment of all malaria infections (which includes the use of quinine, mefloquine, or artemisinin derivatives), and more generally with other prenatal care programmes, including prevention of maternal anaemia and reduction in mother-to-child HIV transmission.

For the future, recent work on the property of parasitized erythrocytes to adhere to chondroitin sulphate A (CSA) expressed by the syncytiotrophoblast and then to accumulate in the placenta gives some hope for preventative or therapeutic interventions. This phenomenon is mediated by parasite variant surface antigens (VSA) expressed on the surface of infected erythrocytes⁴⁴. Placental parasites bind to CSA, but not to the usual ligands of cytoadherence. The expression of a particular VSA by parasites binding to CSA in the placenta elicits variant-specific antibodies that are able to inhibit the cytoadherence of placental parasites to the human syncytiotrophoblast. The decreasing susceptibility to pregnancy-associated malaria with increasing parity is reflected in the acquisition of VSA_CSA-specific antibodies⁴⁵.

Recombinant CSA is efficient in inhibiting and reversing the placental cytoadherence of infected erythrocytes⁴⁶, and thus may constitute the basis of a causative therapy for placental malaria. VSA_CSA-specific antibodies react with placental parasites from all malaria endemic areas⁴⁷, and antibodies raised against the DBL3g domain of PfEMP-1 (the major antigen constituting VSA) also inhibit the binding of placental parasites to CSA⁴⁸. This represents a tremendous opportunity to develop a vaccine against pregnancy-associated malaria in the near future.

	References

Top Abstract Introduction Consequences of malaria during... Effect of malaria prevention... Conclusions and future research References

 

1. Clark HC. The diagnostic value of the placental blood film in aestivo-autumnal malaria. J Exp Med 1915; 22: 427–45[Abstract]
2. McGregor IA. Epidemiology, malaria and pregnancy. Am J Trop Med Hyg 1984; 33: 517–25[Abstract/Free Full Text]
3. Menon R. Pregnancy and malaria. Med J Malaysia 1972; 27: 115–9
4. Sholapurkar SL, Gupta AN, Mahajan RC. Clinical course of malaria in pregnancy—A prospective controlled study from India. Trans R Soc Trop Med Hyg 1988; 82: 376–9[CrossRef][Web of Science][Medline]
5. Nosten F, ter Kuile F, Maelankiri L, Decludt B, White NJ. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 1991; 85: 424–9[CrossRef][Web of Science][Medline]
6. Cot M, Brutus L, Pinell V et al. Malaria prevention during pregnancy in unstable transmission areas: the highlands of Madagascar. Trop Med Int Health 2002; 7: 565–72[CrossRef][Web of Science][Medline]
7. Brabin B. The Risks and Severity of Malaria in Pregnant Women. Geneva: WHO (Applied Field Research in Malaria Reports No. 1), 1991
8. Menendez C. Malaria during pregnancy: A priority area of Malaria research and control. Parasitol Today 1995; 11: 178–83[CrossRef][Web of Science][Medline]
9. Steketee RW, Nahlen BL, Parise ME, Menedendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64: 28–35[Abstract/Free Full Text]
10. Fleming AF. Tropical obstetrics and gynaecology. 1. Anaemia in pregnancy in tropical Africa. Trans R Soc Trop Med Hyg 1989; 83: 441–8[CrossRef][Web of Science][Medline]
11. Jackson DJ, Klee EB, Green SDR, Mokili JLK, Elton RA, Cutting WAM. Severe anaemia in pregnancy: a problem of primigravidae in rural Zaire. Trans R Soc Trop Med Hyg 1991; 85: 829–32[CrossRef][Web of Science][Medline]
12. Matteelli A, Donato F, Shein A et al. Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. Ann Trop Med Parasitol 1994; 88: 475–83[Web of Science][Medline]
13. Shulman CE, Graham WJ, Jilo H et al. Malaria is an important cause of anaemia in primigravidae: evidence for a district hospital in coastal Kenya. Trans R Soc Trop Med Hyg 1996; 90: 535–9[CrossRef][Web of Science][Medline]
14. Brabin BJ, Ginny M, Sapau J, Galme K, Paino J. Consequences of maternal anaemia on outcome of pregnancy in a malaria-endemic area in Papua New Guinea. Ann Trop Med Parasitol 1990; 84: 11–24[Web of Science][Medline]
15. Steer P, Ash Alama M, Wadsworth J, Welch A. Relation between maternal haemoglobin concentration and birth weight in different ethnic groups. BMJ 1995; 310: 489–91[Abstract/Free Full Text]
16. Fullerton WT, Turner AG. Exchange transfusion in the treatment of severe anaemia in pregnancy. Lancet 1962; Jan 13: 75–8
17. Brabin BJ, Verhoeff F. The contribution of malaria. In: McLean AB, Neilson JP (eds) Maternal Morbidity and Mortality. London: RCOG, 2002; 65–78
18. McDermott JM, Slutsker L, Steketee RW, Wirima JJ, Breman JG, Heymann DL. Prospective assessment of mortality among a cohort of pregnant women in rural Malawi. Am J Trop Med Hyg 1996; 55: 66–70[Web of Science][Medline]
19. Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, Breman JG. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 1996; 55: 33–41[Web of Science][Medline]
20. Redd SC, Wirima JJ, Steketee RW, Breman JG, Heymann DL. Transplacental transmission of Plasmodium falciparum in rural Malawi. Am J Trop Med Hyg 1996; 55: 57–60[Web of Science][Medline]
21. Kortmann HF. Malaria and Pregnancy. MD thesis: Drukkerij Elinkwijk, Utrecht, 1972
22. Steketee RW, Wirima JJ, Bloland PB et al. Impairment of a pregnant woman’s acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996; 55: 42–9[Web of Science][Medline]
23. Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health 1999; 4: 5–12[CrossRef][Web of Science][Medline]
24. van Eijk AM, Ayisi JG, ter Kuile FO et al. HIV increases the risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS 2003; 17: 595–603[CrossRef][Web of Science][Medline]
25. Rogerson SJ, Beeson JG. The placenta in malaria: mechanisms of infection, disease and foetal morbidity. Ann Trop Med Parasitol 1999; 93 (Suppl. 1): S35–42
26. Ayisi JG, van Eijk AM, ter Kuile FO et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 2003; 17: 585–94[CrossRef][Web of Science][Medline]
27. Morley D, Woodland M, Cuthbertson WFJ. Controlled trial of pyrimethamine in pregnant women in an African village. BMJ 1964; 1: 667–8
28. Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull WHO 1994; 72: 89–99[Web of Science][Medline]
29. Garner P, Gulmezoglu AM. Drugs for preventing malaria-related illness in pregnant women and death in the newborn (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software
30. Nosten F, ter Kuile F, Maelankiri L et al. Mefloquine prophylaxis prevents malaria during pregnancy: A double-blind, placebo-controlled study. J Infect Dis 1994; 169: 595–603[Web of Science][Medline]
31. Greenwood BM, Greenwood AM, Snow RW, Byass P, Bennett S, Hatib N’jie AB. The effects of malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg 1989; 83: 589–94[CrossRef][Web of Science][Medline]
32. Cot M, Roisin A, Barro D, Yada A, Carnevale P, Breart G. Effect on birth weight of chloroquine chemoprophylaxis during pregnancy: Results of a randomized trial. Am J Trop Med Hyg 1992; 46: 21–7[Abstract/Free Full Text]
33. Cot M, Le Hesran JY, Miailhes P, Esveld M, Etya’Ale D, Breart G. Increase of birth weight following a chloroquine chemoprophylaxis during first pregnancy: results of a randomized trial in Cameroon. Am J Trop Med Hyg 1995; 53: 581–5[Abstract/Free Full Text]
34. Shulman CE, Dorman EK, Cutts F et al. Intermittent sulphadoxine–pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet 1999; 353: 632–6[CrossRef][Web of Science][Medline]
35. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608–14[Abstract/Free Full Text]
36. Nosten F, Vincenti M, Simpson J et al. The effects of mefloquine treatment in pregnancy: A double-blind, placebo-controlled study. Clin Infect Dis 1999; 28: 808–15[Web of Science][Medline]
37. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of anti-malarial regimens containing sulfadoxine–pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51: 515–22[Abstract/Free Full Text]
38. Parise ME, Ayisi JG, Nahlen BL et al. Efficacy of sulfadoxine–pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998; 59: 813–22[Abstract]
39. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the effects of intermittent sulfadoxine–pyrimethamine treatment in pregnancy on parasite clearance and risk for low birthweight in rural Malawi. Ann Trop Med Parasitol 1998; 92: 141–50[CrossRef][Web of Science][Medline]
40. Dolan G, ter Kuile FO, Jacoutot V et al. Bed nets for the prevention of malaria and anaemia in pregnancy. Trans R Soc Trop Med Hyg 1993; 87: 620–6[CrossRef][Web of Science][Medline]
41. D’Alessandro U, Langerock P, Bennett S, Francis N, Cham K, Greenwood BM. The impact of a national impregnated bed net programme on the outcome of pregnancy in primigravidae in The Gambia. Trans R Soc Trop Med Hyg 1996; 90: 487–92[CrossRef][Web of Science][Medline]
42. Shulman CE, Dorman EK, Talisuna AO et al. A community randomised controlled trial of insecticide treated bednets for the prevention of malaria and anaemia among primigravid women on the Kenyan coast. Trop Med Int Health 1998; 3: 197–204[CrossRef][Web of Science][Medline]
43. Browne EN, Maude GH, Binka FN. The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassena-Nankana district, Ghana: a randomized controlled trial. Trop Med Int Health 2001; 6: 667–76[CrossRef][Web of Science][Medline]
44. Beeson JG, Brown GV. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cell Mol Life Sci 2002; 59: 258–71[CrossRef][Web of Science][Medline]
45. Staalsoe T, Megnekou R, Fievet N et al. Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum infected erythrocytes that are associated with protection against placental malaria. J Infect Dis 2001; 184: 618–26[CrossRef][Web of Science][Medline]
46. Chai W, Beeson JG, Kogelberg H, Brown GV, Lawson AM. Inhibition of adhesion of Plasmodium falciparum-infected erythrocytes by structurally defined hyaluronic acid dodecasaccharides. Infect Immun 2001; 69: 420–5[Abstract/Free Full Text]
47. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. Nature 1998; 395: 851–2[CrossRef][Medline]
48. Lekana Douki JB, Traore B, Costa FT et al. Sequestration of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A, a receptor for maternal malaria: monoclonal antibodies against the native parasite ligand reveal pan-reactive epitopes in placental isolates. Blood 2002; 100: 1478–83[Abstract/Free Full Text]

CiteULike    Connotea    Del.icio.us    What's this?

This article has been cited by other articles:

				S. A. Sotimehin, T. I. Runsewe-Abiodun, O. T. Oladapo, O. F. Njokanma, and D. M. Olanrewaju Possible Risk Factors for Congenital Malaria at a Tertiary Care Hospital in Sagamu, Ogun State, South-West Nigeria J Trop Pediatr, October 1, 2008; 54(5): 313 - 320. [Abstract] [Full Text] [PDF]

				F. K. Parekh, J. N. Hernandez, D. J. Krogstad, W. M. Casapia, and O. H. Branch Prevalence and Risk of Plasmodium falciparum and P. vivax Malaria among Pregnant Women Living in the Hypoendemic Communities of the Peruvian Amazon Am J Trop Med Hyg, September 1, 2007; 77(3): 451 - 457. [Abstract] [Full Text] [PDF]

				G. COTTRELL, J.-Y. MARY, D. BARRO, and M. COT THE IMPORTANCE OF THE PERIOD OF MALARIAL INFECTION DURING PREGNANCY ON BIRTH WEIGHT IN TROPICAL AFRICA Am J Trop Med Hyg, May 1, 2007; 76(5): 849 - 854. [Abstract] [Full Text] [PDF]

				G. COTTRELL, J.-Y. MARY, D. BARRO, and M. COT IS MALARIAL PLACENTAL INFECTION RELATED TO PERIPHERAL INFECTION AT ANY TIME OF PREGNANCY? Am J Trop Med Hyg, December 1, 2005; 73(6): 1112 - 1118. [Abstract] [Full Text] [PDF]

				S. Jafari-Guemouri, N. T. Ndam, G. Bertin, E. Renart, S. Sow, J.-Y. Le Hesran, and P. Deloron Demonstration of a High Level of Parasite Population Homology by Quantification of Plasmodium falciparum Alleles in Matched Peripheral, Placental, and Umbilical Cord Blood Samples J. Clin. Microbiol., June 1, 2005; 43(6): 2980 - 2983. [Abstract] [Full Text] [PDF]

				G. Bertin, N. T. Ndam, S. Jafari-Guemouri, N. Fievet, E. Renart, S. Sow, J.-Y. Le Hesran, and P. Deloron High prevalence of Plasmodium falciparum pfcrt K76T mutation in pregnant women taking chloroquine prophylaxis in Senegal J. Antimicrob. Chemother., May 1, 2005; 55(5): 788 - 791. [Abstract] [Full Text] [PDF]

This Article Abstract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Search for citing articles in: ISI Web of Science (10) Request Permissions Disclaimer Google Scholar Articles by Cot, M Articles by Deloron, P Search for Related Content PubMed PubMed Citation Articles by Cot, M Articles by Deloron, P Related Collections Infectious Diseases Obstetrics and Gynaecology Social Bookmarking          What's this?

Online ISSN 1471-8391 - Print ISSN 0007-1420

Copyright © 2009 Oxford University Press

Oxford Journals Oxford University Press

• Site Map
• Privacy Policy
• Frequently Asked Questions

Other Oxford University Press sites: Oxford University Press Oxford Journals China Oxford Journals Japan American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics